Fatigue News and Research

RSS

Study identifies atrial fibrillation as a growing and serious global health problem

Atrial fibrillation, long considered the most common condition leading to an irregular heartbeat, is a growing and serious global health problem, according to the first study ever to estimate the condition's worldwide prevalence, death rates and societal costs.

18 Dec 2013

Toddlers’ bedtime resistance may contribute to sleep problems

The bedtime you select for your toddler may be out of sync with his or her internal body clock, which can contribute to difficulties for youngsters attempting to settle in for the night, according to a new University of Colorado Boulder study.

17 Dec 2013

Taking simple steps to stay healthy while traveling can make holidays more enjoyable, says expert

Traveling long distances during the holidays -- whether by car, plane or train -- is a common custom for many Americans, but taking health precautions for the journey isn't often at the top of to-do lists. Taking some simple steps to stay healthy while traveling can make the holidays more enjoyable and safe, according to a Mayo Clinic expert.

17 Dec 2013

Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC

Erlotinib as first-line therapy in patients with advanced non-small-cell lung cancer is equivalent to chemotherapy with regard to overall survival, an “all-comers” phase II trial has shown.

16 Dec 2013

Cetuximab fails in second-line combination for recurrent NSCLC

Results from a phase III trial indicate that cetuximab should not be given alongside chemotherapy in patients with recurrent non-small-cell lung cancer after platinum-based therapy.

13 Dec 2013

Methodology needed to diagnose quality of life of individual cancer patients or survivors

Due to improved treatments and technologies, more children than ever are surviving cancer. Unfortunately, about 70 percent of these children experience late effects from their disease and treatment 30 years after their cancer diagnosis, which University of Florida Health researchers say significantly impact their quality of life.

13 Dec 2013

Researchers develop first test to identify acute mountain sickness

The first test to identify acute mountain sickness has been developed by a team of researchers in Italy and France and is presented today at EuroEcho-Imaging 2013. The test could revolutionise trekking and climbing by predicting who will develop the potentially deadly condition so they can avoid high altitudes, ascend more gradually or take preventative medication.

12 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

New study aims to determine prevalence of pediatric chronic fatigue syndrome in Chicago area youth

The prevalence of chronic fatigue syndrome in children and the significant impairment it causes to their physical functioning, school attendance and performance, and extracurricular activities, are at the root of a new Chicago-based study led by DePaul University psychologist Leonard A. Jason.

11 Dec 2013

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.

11 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

Endocrinologist suggests parents to check their child's blood sugar more often during holidays

Indulgences abound during the holidays—from family gatherings to parties with friends and even stockings stuffed with goodies from Santa. For children with diabetes, overindulging on the delicacies of the season could result in more than a stomach ache, it could mean a trip to the emergency room.

10 Dec 2013

Pemetrexed, paclitaxel regimens equally effective in NSCLC

PointBreak trial results suggest that pemetrexed- and paclitaxel-based chemotherapy offer comparable survival outcomes and tolerability for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) but with differing toxicity profiles.

10 Dec 2013

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Takeda Pharmaceutical Company Limited today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

10 Dec 2013

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops targeted, antibody-based anticancer therapeutics, today announced the first clinical findings with SAR650984 reported in an oral presentation at the ASH annual meeting. The data are from an ongoing Phase I trial assessing this CD38-targeting therapeutic antibody in patients with CD38-positive MM or other hematologic malignancy.

10 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

Fatigue News and Research

Study identifies atrial fibrillation as a growing and serious global health problem

Toddlers’ bedtime resistance may contribute to sleep problems

Taking simple steps to stay healthy while traveling can make holidays more enjoyable, says expert

Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC

Cetuximab fails in second-line combination for recurrent NSCLC

Methodology needed to diagnose quality of life of individual cancer patients or survivors

Researchers develop first test to identify acute mountain sickness

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

New study aims to determine prevalence of pediatric chronic fatigue syndrome in Chicago area youth

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Endocrinologist suggests parents to check their child's blood sugar more often during holidays

Pemetrexed, paclitaxel regimens equally effective in NSCLC

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

New guide offers employers online and interactive toolkit to help support employees with cancer

The Medicines Company, Boston Scientific announce co-promotion agreement for Promus PREMIER stent system

Eisai reports new data analyses on FYCOMPA (Perampanel) at AES meeting

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News